#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial

So far this year Allogene has barreled out of left field with a pair of the most experienced CAR-T execs in the industry steering the new business to a record-setting (for now) IPO. And they’re headed straight into their first update on data for what an off-the-shelf CAR-T can do for patients suffering from acute lymphoblastic leukemia — with what they believe is a manageable safety profile.